Start the conversation
Insys Therapeutics Inc. (NASDAQ: INSY) - our "War on Pain" biotech play - has given us a profit of more than 16% since we recommended the stock just two weeks ago.
That's just for starters.
The U.S. Food and Drug Administration (FDA) today approved the final "product label" for the company's new synthetic-marijuana drug - which means Insys can bring this new therapy to market in August.
Investors who specialize in drug stocks are always trying to pull profits from trades based on the three-step FDA phalanx that up-and-coming biotechs must navigate to finally get a new drug to market.
But if you really want to cash in, commercialization is the "triggering event" that can make that happen.
And that's exactly where Insys is right now.
Let me give you a little bit of context here - before I explain exactly what's going to happen next...
This is premium content for Private Briefing subscribers only.